RxDoctor Payments Data

Kathleen Adkins

Nurse Practitioner · Washington Court House, OHNPI 1003122094

Payments from drug & device makers

$1,717in general payments, 2019–2025

Across 109 payments — averaging $15.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$357
  • Lilly USA, LLC$307
  • AbbVie$258
  • Merck$250
  • Abbott$84
  • Vanda Pharmaceuticals Inc.$61
  • plus $400 from 13 others

What the payments were for

  • Food & beverage$1,717100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,717 in reported general payments places this provider in the 90th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$1,112
Medicare patients
22
Services billed
31

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin57$64,664
OzempicSemaglutide42$49,425
Tresiba Flextouch U-200Insulin Degludec59$48,717
EliquisApixaban18$22,870
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$18,509
TrulicityDulaglutide18$18,048
JanumetSitagliptin Phos/Metformin Hcl18$17,093
MounjaroTirzepatide16$16,717
XareltoRivaroxaban13$15,963
SymbicortBudesonide/Formoterol Fumarate24$7,898
SynjardyEmpagliflozin/Metformin Hcl12$7,214
Lacosamide12$6,501
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$5,113
Albuterol Sulfate HfaAlbuterol Sulfate208$5,081
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate22$4,342

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy$35$71,87869 claims
Novo NordiskOzempic$357$49,42542 claims
Lilly USA, LLCTrulicity, Mounjaro$307$34,76534 claims
PfizerEliquis$58$22,87018 claims
GSKTrelegy Ellipta$17$18,50924 claims
MerckJanumet$250$17,09318 claims
AstraZenecaSymbicort$31$7,89824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Washington Court House

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →